Urinary Markers Show Promise in ASD - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Urinary Markers Show Promise in ASD

Findings add to growing evidence in favor of microbiome-associated metabolite analysis for ASD screening and stratification

  • June 15, 2026

  • 3 min

Share

Objective:

To evaluate the potential of urinary microbially derived metabolites as a diagnostic tool for identifying a subgroup of children with autism spectrum disorder (ASD).

Approach:
    Key Findings:
    • Initial testing identified numerous metabolites that differed between ASD and control groups.
    • 90% of children with ASD had at least one markedly elevated metabolite, with a sensitivity of 90% and specificity of 100%.
    • In a separate validation analysis, sensitivity was 78% while specificity remained 100%.
    • Key metabolites distinguishing groups included p-cresol, p-cresol sulfate, indole-3-acryloyl glycine, phenylacetylglutamine, and arabinitol.
    Interpretation:

    Limitations:
    • Study included fewer than 100 participants.
    • Excluded children with known genetic causes of autism.
    • Did not collect information on diet, medication use, or body mass index.
    Conclusion:

Original Source(s)

Urinary Markers Show Promise in ASD

  • June 15, 2026

Related Content

Aptamer Tests Face the Validation Challenge

Clinical adoption will require reproducibility, quality control, and evidence of diagnostic utility

  • October 6, 2026

  • 3 min
FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

ACS report: Lung cancer deaths plunge as survival doubles

Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.